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ABSTRACT 
Phenylalanine hydroxylase (PAH) is an enzyme that catalyses the hydroxylation of 
phenylalanine into tyrosine in the liver, which is the rate-limiting step in phenylalanine 
catabolism. PAH is a non-heme iron-dependent enzyme that also requires tetrahydrobiopterin 
(BH4) as cofactor to perform catalysis. PAH dysfunction results in phenylketonuria (PKU), 
characterized by neurotoxic accumulation of phenylalanine. PKU is caused by mutations in 
the PAH gene, usually resulting in a misfolding of PAH. A novel approach to treating 
misfolding diseases in general, is the use of pharmacological chaperones – small molecules 
that can stabilize the native form of a protein and thus prevent misfolding and rescue protein 
function.  
The aim of this Master project was to combine virtual and experimental methods to identify 
compounds that could act as pharmacological chaperones for PAH. The docking program 
Glide was used to screen a virtual library, and the compounds with the highest binding 
affinities were tested experimentally to validate their interactions with PAH, by testing 
thermostability and enzymatic activity of PAH in the presence of the compounds. 
Target-based virtual screening and subsequent experimental validation identified a compound 
with a potential in pharmacological chaperone therapy for PKU. This compound had a 
significant protective effect on PAH activity, and its specificity and thermodynamic binding 
properties should be further investigated. 
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ABBREVIATIONS 
4α-OH-BH4: Pterin-4α-carbinolamine 
5-OH-Trp:  5-hydroxytryptophan 
AAAH:  Aromatic amino acid hydroxylase 
AAPA: (2S, 3R)-3-amino-2-hydroxy-4-phenylbutyric acid 
BH4:   (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin 
BSA:   Bovine serum albumin 
CNS:  Central nervous system 
DHFR:  Dihydrofolate reductase 
DHPR:  Dihydropteridin reductase 
DSF:   Differential scanning fluorimetry 
DMSO:  Dimethyl sulfoxide 
FDR:  False discovery rate 
GIT:  Gastrointestinal tract 
HEPES:  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC:  High performance liquid chromatography 
eHTS:  Experimental high throughput screening 
HPA:   Hyperphenylalaninemia 
hPAH:  Human phenylalanine hydroxylase 
ITC:  Isothermal titration calorimetry 
L-DOPA:  (S)-3,4-dihydroxyphenylalaninne 
LNAAs:  Large neutral amino acids 
L-Phe:  L-phenylalanine 
L-Tha:  L-thienylalanine 
L-Trp:  L-tryptophan 
L-Tyr:  L-tyrosine 
L-Nle:  L-norleucine 
LSDs:   Lysosomal storage diseases  
PAH:   Phenylalanine hydroxylase 
PAL:  Phenylalanine ammonia lyase 
PCD:   Pterin carbinolamine dehydratase  
PCR:   Polymerase chain reaction 
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PDB:   Protein Data Bank 
PKU:   Phenylkentonuria 
RMSD:  Root-square-mean deviation 
SD:  Standard deviation 
SEM:  Standard error of the mean 
TH:   Tyrosine hydroxylase 
THD:   Tyrosine hydroxylase deficiency 
TPH:   Tryptophan hydroxylase 
vHTS:  Virtual high throughput screening 
wt-PAH: Wild-type PAH 
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1  INTRODUCTION 
1.1  Phenylalanine hydroxylase 
Phenylalanine hydroxylase (PAH) is an enzyme that catalyzes the hydroxylation of 
phenylalanine (L-Phe) into tyrosine (L-Tyr), which is the rate limiting step in the degradation 
of excess L-Phe in the liver. PAH dysfunction is caused by mutations in the PAH gene, and 
results in phenylketonuria (PKU), characterized by neurotoxic accumulation of phenylalanine 
(1, 2). 
1.1.1 Catalytic mechanism 
 PAH is a non-heme iron- and (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)-dependent 
enzyme, and the catalysis also requires O2 as additional substrate. The cofactor BH4 is the 
source of electrons in the catalytic mechanism, and the complete catalytic cycle, including the 
regeneration of the cofactor, is illustrated in Figure 1-1. Oxygen binds to Fe2+, which is 
activated by BH4, forming a Fe2+-O-O-BH4 complex. The O-O bond is cleaved, and a 
Fe(IV)=O intermediate is formed, hydroxylating phenylalanine to tyrosine. During catalysis, 
BH4 is hydroxylated to pterin-4α-carbinolamine (4α-OH-BH4), and after each catalytic cycle 
BH4 has to be regenerated. The enzyme pterin carbinolamine dehydratase (PCD) converts 4α-
OH-BH4 to q-BH2, which is converted to BH4 by either dihydropteridin reductase (DHPR) or 
through BH2 by dihydrofolate reductase (DHFR) (see reviews (3-5)). 
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Figure 1-1: The phenylalanine hydroxylating system, showing hydroxylation of L-Phe into L-Tyr by PAH, and 
regeneration cycle for the cofactor BH4. 
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1.1.2 Structure and regulation  
PAH is a tetramer consisting of four monomers arranged as two dimers bound together 
(Figure 1-2). Each monomer has three domains: an N-terminal regulatory domain, a catalytic 
domain, and a C-terminal oligomerization domain (Figure 1-3). 
 
Figure 1-2: The PAH tetramer. Each monomer has a distinct colour and all domains are included (PDB entries 
2pah and 1phz). The iron atom is shown as an orange sphere in each of the four active sites. 
 
The crystal structures have been solved for dimeric human PAH (catalytic domain) (6), 
tetrameric human PAH (oligomerization domain plus catalytic domain) (7), and for dimeric 
rat PAH (regulatory domain plus catalytic domain) (8).  
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Figure 1-3: The PAH monomer showing the domain organization. The regulatory N-terminal is shown in yellow 
(residues 1-117, only 19-117 shown), the catalytic domain in red (residues 118-410) with the iron atom as an 
orange sphere, and the oligomerization C-terminal in green (residues 411-452) (PDB entries 2pah and 1phz). 
 
The regulatory domain is located at the N-terminal. PAH is activated by phosphorylation of 
Ser16 by a protein kinase (9, 10), and by binding of phenylalanine (11). These regulatory 
mechanisms act synergistically, enhancing each other (10). In addition to its role as cofactor 
in the catalytic mechanism, BH4 is also a negative regulator of PAH activity at high 
concentrations (12). The oligomerization domain is located at the C-terminal and it is 
responsible for dimerization and tetramerization. 
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The catalytic domain consists of an active site with an iron atom coordinated to three amino 
acids, called a 2-His-1-carboxylate facial triad-motif (13), and two binding pockets; one 
cofactor binding site and one substrate binding site. Figure 1-4 shows the amino acids 
important for coordination of the iron atom (His285, His290 and Glu330), binding of the 
cofactor (especially pi-pi stacking through Phe254 and hydrogen bonding to Glu286), and 
binding of substrate, in particular His285 (pi-pi stacking), Arg270, Ser349 and Thr278 (14, 
15). 
 
 
Figure 1-4: The active site with the cofactor and substrate binding sites, showing the most important amino 
acids involved in cofactor and substrate binding and coordination of the iron atom (PDB 1mmk). The amino 
acids are shown as sticks and colored by atom type. BH4 is shown in blue in the coafactor binding site, and the 
substrate analog thienylalanine (L-Tha) is shown in yellow in the substrate binding site. Iron is shown as an 
orange sphere coordinating to three amino acids. 
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When the substrate binds to PAH, it is believed that large conformational changes occur. Only 
binding of the substrate analogous thienylalanine (L-Tha) and norleucine (L-Nle) have been 
solved by x-ray crystallography, but it is reasonable to assume that binding of phenylalanine 
is similar. The crystal structures of the substrate analogous in complex with the catalytic 
domain of PAH, were solved by Andersen et al in 2003 (16), and demonstrate that 
conformational changes occur in the catalytic domain upon substrate binding; most 
importantly, Tyr138 moves from a surface position to a position inside of the active site. The 
structural changes in the full length enzyme with intact regulatory domain have not yet been 
solved experimentally. However, there is experimental evidence of an increased exposure of 
the regulatory domain upon substrate binding (17), and it has been postulated that the 
regulatory domains rearrange to form an allosteric L-Phe binding site (18). In an alternative 
model, L-Phe is proposed to bind exclusively at the four catalytic sites in the tetramer, 
without any allosteric L-Phe binding site in the regulatory domain (19, 20). Direct 
experimental evidence for the proposed model of L-Phe substrate activation of the full-length 
PAH enzyme, represents a challenge for the future and require further structural information 
on the full-length enzyme. 
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1.2 The aromatic amino acid hydroxylases  
PAH is part of an enzyme family called the aromatic amino acid hydroxylases (AAAHs), 
which also include tyrosine hydroxylase (TH) and the tryptophan hydroxylases (TPH1 and 
TPH2). They all catalyse the hydroxylation of an aromatic amino acid substrate requiring 
BH4, O2 and Fe2+, and are structurally very similar (Figure 1-5). Dysfunction caused by 
mutations in TH and the TPHs have been associated with neurological and psychiatric 
disorders (21).  
 
Figure 1-5: Superimposition of the catalytic domains of PAH (red), TH (yellow) and TPH1 (green) (PDB 
entries 1j8u, 1toh and 1mlw). The cofactor in complex with PAH is shown as sticks (blue), and iron as an orange 
sphere.  
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1.2.1 Tyrosine hydroxylase 
TH is found in the central nervous system (CNS), the peripheral sympathetic neurons and in 
the adrenal medulla (22), where it catalyses the hydroxylation of L-Tyr into L-DOPA, which 
is the rate-limiting step in the synthesis of the catecholamines dopamine, noradrenalin and 
adrenaline (Figure 1-6). Dysfunctions in TH are associated with the genetic neurological 
disorder tyrosine hydroxylase deficiency (THD), characterized by autosomal recessive 
DOPA-responsive dystonia and juvenile Parkinsonism, and TH levels are also severely 
reduced in Parkinson’s disease  (23-25). 
 
 
Figure 1-6: PAH catalysis – hydroxylation of L-Phe into L-Tyr in the liver, and subsequent TH catalysis – 
hydroxylation of L-Tyr into L-DOPA in neuroendocrine tissues.  
 
1.2.2 Tryptophan hydroxylase  
TPH catalyses the hydroxylation of tryptophan (L-Trp) to 5-hydroxytryptophan (5-OH-Trp), 
which is the rate-limiting step in the synthesis of serotonin (Figure 1-7). Serotonin is further 
converted to melatonin. TPH exists as two isoforms, encoded by two genes: TPH1 is mainly 
found in the gastrointestinal tract (GIT) and in the pineal gland, where melatonin is produced, 
while TPH2 seems to be found exclusively in the brain and it is the main TPH isoform in the 
CNS (26). Serotonin has an important role in regulating sleep, mood, appetite and sexual 
behaviour, and mutations in the TPHs have been associated with various psychiatric 
disorders, such as depression, suicidal behaviour and hyperactivity (27-29).    
 
Figure 1-7: TPH catalysis – hydroxylation of L-Trp into 5-OH-Trp in GIT and CNS. 
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1.3 Phenylketonuria  
Phenylketonuria (PKU), first described by Fölling in 1934 (30), and probably better known as 
Föllings disease in Norway, is an inborn error of L-Phe metabolism caused by mutations in 
the gene encoding PAH.  Defects in PAH lead to raised plasma levels and accumulation of 
phenylalanine (hyperphenylalaninemia; HPA), which impair brain function and development, 
if left untreated (1). In Norway, about 1:13000 newborns are diagnosed with PKU (31). 
 
PKU is inherited as an autosomal recessive condition, i.e. both alleles have to be mutated. 
There are over 500 different mutations in the PAH gene, most of them causing a misfolding of 
PAH and subsequent decreased conformational stability (32, 33) 
(http://www.pahdb.mcgill.ca). It is distinguished between classical PKU, mild PKU and even 
non-PKU HPA, depending on the degree of phenylalanine accumulation and loss-of-PAH-
function. Classical PKU has little or no PAH activity (plasma L-Phe > 1200 µM), whereas 
mild PKU and non-PKU HPA has some PAH activity (plasma L-Phe 360-1200 µM and 120-
600 µM, respectively) (34). A forth type, generally known as “malignant” PKU is not caused 
by PAH-mutations, but by mutations in the genes encoding for enzymes involved in BH4 
synthesis or regeneration, and in addition to HPA, this form is also characterized by severe 
deficiency in monoamine neurotransmitters (catecholamines and serotonin) (5). 
Newborn screening tests and life-long dietary treatment has been successful in preventing 
brain damage resulting from PKU. However, a lower IQ than the average is observed for 
individuals with PKU, even with a phenylalanine-restricted diet from birth. Dietary treatment 
is also very demanding, often leading to malnutrition and psychosocial complications (35). 
Therefore, alternative treatments have appeared over the recent years, including treatment 
with synthetic BH4 (Kuvan®), which has been shown to reduce plasma L-Phe levels and 
increase L-Phe tolerance in mild forms of PKU (36, 37). Also, gene therapy (38, 39), 
supplementation with large neutral amino acids (LNAAs) (40) and enzyme replacement 
therapy with phenylalanine ammonia lyase (PAL) (41), are alternative approaches which are 
being investigated for treating PKU.   
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1.4 Protein folding and misfolding diseases 
Folding of proteins occurs because of interactions between the amino acids in the primary 
structure, and correct folding is required for a functional protein. Proteins fold into the 
conformation that has the lowest free energy, and the free energy difference (ΔG) between the 
folded state (F) and the unfolded state (U) determines the conformational stability of the 
protein (42, 43).  
Mutations in the amino acid sequence can cause misfolding or denaturation of the protein. 
Misfolded proteins are usually degraded, which leads to deficiency in the protein function, as 
seen for PKU, which is designated a loss-of-function misfolding disease. Gain-of-function 
misfolding diseases also exist, in which the mutant protein gains a toxic function where it is 
resistant to degradation and aggregates, forming amyloid deposits, as observed in Alzheimer’s 
disease and Parkinson’s disease (44). 
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1.5 Pharmacological chaperones  
The concept of pharmacological chaperones comes from the term molecular chaperones. 
Molecular chaperones are large proteins that facilitate and assist protein folding, being part of 
the cellular quality control system that either assists misfolded proteins in refolding, or 
degrades them (45). Pharmacological chaperones are small molecules that stabilize the native 
folded conformation of a protein by interacting with residues in the active site, preventing or 
rescuing misfolding (46-48). These molecules therefore have a potential in the treatment of 
various misfolding diseases, such as PKU. Successful therapeutic use of pharmacological 
chaperones has been described for several of the lysosomal storage disorders (LSDs) and 
cystic fibrosis (see review (49)). 
In fact, after being on the market for several years, synthetic BH4 was discovered to act like a 
natural pharmacological chaperone for PAH. It has been shown to stimulate PAH activity 
partly by correcting mutant-PAH misfoldning in some PKU patients (36, 37). Additional 
small molecule PAH chaperones have recently been identified by Pey et al. (50), and Santos-
Sierra et al. (51).  The crystal structure of one of these pharmacological chaperones, usually 
referred to as compound IV (5,6-dimetyl-3-(4-methyl-2-pyridinyl)-2-thioxo-2,3-
dihydrothieno[2,3-d]pyrimidin-4(1H)-one), in complex with hPAH was solved by 
Torreblanca et al (52) in 2012, and demonstrated that compound IV bound in the active site, 
coordinating to iron through a nitrogen atom (N1), as shown in Figure 1-8. It is a weak 
inhibitor of PAH activity, but it still has the ability to stabilize PAH (both wild type and 
mutant forms) in vitro and in vivo (50).  
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Figure 1-8: Binding of compound IV in the active site of PAH (PDB 4anp and 1mmk). Compound IV is 
represented as green sticks, and coordination between N1 and iron (orange sphere) is shown. BH4 is displayed in 
blue, and L-Tha in yellow. The protein is omitted for clarity, but important amino acids are shown as sticks. 
 
 
Selectivity towards PAH represents a challenge, as the AAAHs are structurally very similar, 
and chaperoning (or inhibitory) effect on TH and the TPHs could results in unacceptable side-
effects. Some of the chaperones are tested on the other AAAHs, but the selectivity is not fully 
established (53).   
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1.6 Computational drug design 
Computer-aided drug design is increasingly being utilized both in academic research and in 
the pharmaceutical industry. Traditionally, experimental high throughput screening (eHTS) 
has been a common way of identifying new leads in the field of drug discovery. It requires a 
set of known ligands that are experimentally screened against a target. With virtual high 
throughput screening (vHTS), larger chemical diversity can be explored, and to a reduced cost 
compared to eHTS. In the following lead optimization process where hits/leads obtained in 
the drug discovery phase are being further developed into drugs, computational approaches 
provide the opportunity to analyze the interactions of the potential leads with their target in an 
earlier stage, and optimizing the lead to increase the probability of it becoming an actual drug 
(54-56).  
Target-based virtual screening, or molecular docking, can be defined as the comprehensive 
process of searching a virtual library of ligands by positioning them in the binding site in a 
three dimensional structure of the target protein, and scoring the binding affinity. The main 
principles in docking is a search algorithm, responsible for positioning the ligands in the 
active site of the protein in various orientations, and a scoring function, that determines 
whether these orientations are the most energetically favourable (57). With the increasing 
amount of potential protein targets available, target-based virtual screening provides a 
powerful tool in the early stages of drug discovery, and it has been successfully used to 
identify therapeutically active compounds, such as several anti-viral agents (58).   
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2 AIMS OF THE PROJECT 
The overall aim of this Master project was to find compounds that could bind to and possibly 
stabilize PAH and thus act as pharmacological chaperones. Towards this aim we chose to 
screen a virtual database of ligands by molecular docking and to experimentally test the most 
promising ligands by measuring their effect on the thermal stability of PAH and on the 
preservation of enzymatic activity. The compounds that stabilize PAH can be considered 
potential pharmacological chaperones for PAH, which later might be derivatized and 
optimized for future treatment of PKU. 
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3 MATERIALS AND METHODS 
3.1 Materials 
SOFTWARE 
Program Version Provider 
Maestro 9.5 Schrödinger LLC 
LigPrep 2.7 Schrödinger LLC 
Protein Preparation Wizard - Schrödinger LLC 
Glide 6.0 Schrödinger LLC 
Epik 2.5 Schrödinger LLC 
Discovery Studio 3.5 Accelrys Inc. 
Accelrys Draw 4.1 Accelrys Inc. 
GraphPad Prism 6 GraphPad Software 
Canvas 1.7 Schrödinger LLC 
 
INSTRUMENTS 
Method Instrument Provider 
Concentration measurements Nanodrop ND-1000 Saveen Werner 
Centrifugation Centrifuge 5810R Eppendorf 
Weighing Melter Toledo AB104-S Bergman 
pH measurements 691 pH Meter Metrohm 
DSF LightCycler 480 Roche Applied Science 
HPLC 1200 Infinity series Agilent Technologies 
 
CHEMICALS 
Name Provider 
5000X SYPRO orange Sigma Aldrich 
Acetic acid (CH3COOH) Sigma Aldrich 
Ammonium iron (II) sulphate hexahydrate  
((NH4)2Fe(SO4)2 ・H2O) 
Sigma Aldrich 
Bovine serum albumin (BSA) Sigma Aldrich 
Catalase Sigma Aldrich 
Compound IV (5,6-dimethyl-3-(4-methyl-2-pyridinyl)-2-thioxo-
2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one) 
Maybridge LTD 
Compound 1 (5-(3′-hydroxybenzyl)hydantoin) Sigma Aldrich 
Compound 2 (N-(4-hydroxy-6-quinazolinyl)acetamide) Sigma Aldrich 
Compound 3 (4,4′-Diamino[1,1′-biphenyl]-3,3′-diol) Sigma Aldrich 
Compound 4 (3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1H-1,2,4-
triazol-5-amine) 
Sigma Aldrich 
Compound 5 (Tyr-Phe) Sigma Aldrich 
Compound 6 ((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyric acid Sigma Aldrich 
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hydrochloride) 
Compound 7 (Met-Leu-Phe acetate salt) Sigma Aldrich 
Compound 8 ((R,S)-4-Fmoc-3-carboxymethyl-piperazin-2-on) Sigma Aldrich 
Compound 9 (7-Hydroxycoumarinyl-4-acetic acid) Sigma Aldrich 
Compound 10 (L-Glutamic acid γ-benzyl ester) Sigma Aldrich 
Compound 11 (2-N-Fmoc-amino-3-(2-N-Boc-amino-pyrrolidinyl) 
propionic acid) 
Sigma Aldrich 
Compound 12 (Phe-Arg β-naphthylamide dihydrochloride) Sigma Aldrich 
Compound 13 (2-Acetyl-1,3-indanedione) Sigma Aldrich 
Compound 14 (Diminazene aceturate) Sigma Aldrich 
Compound 15 (fmoc-D-2-aminomethylphe(boc)) Sigma Aldrich 
Compound 16 (1,3-Diiminoisoindoline) Sigma Aldrich 
Compound 17 (Nα-Benzoyl-Asn-Gly-Thr amide trifluoroacetate 
salt) 
Sigma Aldrich 
Compound 18 ((S)-(-)-2-t-butyl-2-piperazinecarboxamide) Sigma Aldrich 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Distilled water Milli-Q 
Dithiothreitol (DDT) Sigma Aldrich 
Ethanol Sigma Aldrich 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Sigma Aldrich 
Hydrogen chloride (HCl) VWR International 
Propan-1-ol Sigma Aldrich 
Sodium hydroxide (NaOH) Sigma Aldrich 
Tetrahydrobiopterin (BH4) Schircks Laboratories 
L-Tyrosine Sigma Aldrich 
L-Phenylalanine Sigma Aldrich 
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BUFFERS AND SOLUTIONS 
 
FPLC-buffer: 
Concentration Chemical Mw  
20 mM HEPES 238,3 g/mol  
200 mM NaCl 58,44 g/mol 
pH is adjusted to 7 with NaOH. 
Kept at -20 ˚C. 
 
 
HEPES-buffer: 
Concentration Chemical Mw  
250 mM HEPES 238,3 g/mol  
pH is adjusted to 7 with NaOH 
Kept at -20 ˚C. 
 
Stop solution: 
Concentration  Chemical Initial concentration 
98 % (v/v) Ethanol Absolute 
2 % (v/v) Acetic acid < 99,8 % 
Kept at -20 ˚C. 
 
HPLC-buffer: 
Concentration  Chemical Initial concentration 
2 % (v/v) 1-Propanol Absolute 
0,1 % (v/v) Acetic acid < 99,8 % 
 
 
ENZYME 
Recombinant human wild-type PAH was expressed and purified to homogeneity according to 
the protocol described by Martinez et al. (59) , and was provided by Ali Javier Sepulveda, 
technician in the Biorecognition group.  
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3.2 Target-based virtual screening 
The Sigma library, which contains 66374 compounds, and is provided by Sigma-Aldrich and 
downloaded from Zinc (60, 61), was screened to identify compounds that fit with specific 
binding pockets in the correctly folded PAH structure, and therefore could be potential 
pharmacological chaperones for the enzyme. In order to test and validate the method, we 
performed a cross-docking of ligands that we know the binding mode of, including BH4, 
compound IV and two substrate analogues for PAH (L-Tha and L-Nle)   
The docking program used in this project is Glide, which is part of a software package 
provided by Schrödinger (62, 63). 
3.2.1 The Glide docking procedure 
Before the docking job can be started, the protein and ligand structures need to be prepared, 
and the receptor grid, which is the area on the protein that is searched when attempting to 
dock the ligands, must be defined. Protein preparation involves assigning atom types, bond 
orders, partial charges and protonation states for the PDB-structure serving the role as the 
target protein. Ligand preparation ensures that the ligands are appropriate for docking, by 
assigning atom types and adding hydrogens and protonation states. Protein Preparation 
Wizard (64, 65) and LigPrep (65, 66) are provided from Schrödinger for these purposes. 
Glide can perform flexible docking or rigid docking. In flexible docking, different ligand 
conformations are generated internally during the docking process, whereas for rigid docking 
only one ligand conformation is allowed, which is translated and rotated relative to the protein 
receptor. The protein receptor is treated by Glide as a rigid structure both in rigid and flexible 
docking. Glide has three different modes of precision; high throughput virtual screening 
(HTVS), standard precision (SP) and extra precision (XP). HTVS provides a rapid screen of 
large databases, but the conformational sampling is restricted. SP docking is the default, and it 
is suitable for screening large number of ligands of unknown quality. XP can be used on 
ligand poses that get a high score from the SP docking, and is more extensive (67). 
Glide uses multiple search algorithms in a hierarchical manner where the ligands pass through 
a series of filters that evaluate the ligand’s interactions with the protein receptor. The binding 
affinity is predicted by the scoring function GlideScore: 
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GScore = 0,05*vdW + 0,15*Coul + Lipo + Hbond + Metal + Rewards + RotB + Site 
Van der Waals (vdW) and Coulomb energy (Coul) are calculated with reduced net ionic 
charges on groups with formal charges. The lipophilic term (Lipo) rewards favourable 
hydrophobic interactions. The hydrogen-bonding term (HBond) is separated into different 
weighted components depending on the charge on the hydrogen donors and acceptors. The 
metal binding includes only the interactions with anionic or highly polar atoms (if the net 
metal charge is positive). The rewards-term rewards or penalizes various features that are not 
mentioned separately. RotB adds a penalty for freezing rotatable bonds. The site-term rewards 
polar but non-hydrogen-bonding atoms in a hydrophobic region.  
The protein-and ligand preparation procedures, and the search and scoring functions are 
thoroughly explained in the Glide User Manual (67). 
3.2.2 Choice of PDB structures 
There are several crystal structures of PAH available in the Protein Data Bank (PDB), and 
which ones to use as target structures, was decided based on completeness of the structure, 
charge on the iron atom and the presence of cofactor or substrate analogues in the active site. 
For the cross-docking we ended up using PDB 1j8u (representing the catalytic domain) as the 
protein receptor (68).  
When docking the Sigma library, we have also considered alternative binding sites on the 
surface of the protein, in addition to the active site. Two potential binding sites were 
identified using LIGSITE (69); one in the interface between two monomers in a dimer, and 
the other one in the interface between two dimers in the tetramer (Figure 3-1). Ij8u only 
represents the catalytic domain. There is one PDB file (2pah) of tetrameric PAH (7), but this 
structure lacks the regulatory domain. Therefore, a hybrid structure was made out of 1j8u, 
2pah and 1phz (8), the last one is a rat structure of PAH with an intact regulatory domain. To 
prepare a hybrid structure of tetrameric hPAH, the amino acids of the regulatory domain 
(from rat) were mutated to the corresponding human residues.  
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Table 3-1: Details of the PDB files used. Hetero-groups are the non-amino acid content of the structure. 
PDB 
entry 
Organism Resolution (Å) Residues Domain Hetero-
groups 
1j8u Homo 
sapiens 
1.5 118-424  Catalytic domain Fe2+, BH4 
2pah  Homo 
sapiens 
3.1 118-452  Catalytic domain and 
oligomerization domain 
Fe3+ 
1phz  Rattus 
norwegicus 
2.2 19-427 Catalytic domain and 
regulatory domain 
Fe3+ 
 
 
Figure 3-1: Binding pockets on the protein surface, illustrated as blue spheres (PDB 1j8u, 2pah and 1phz). The 
domains are shown in different colours.  a) interface between monomers b) interface between dimers 
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3.2.3 Cross-docking of selected compounds 
Cross-docking refers to docking of a ligand from one crystal structure of a protein into a 
different crystal structure of the same protein, to see whether the ligand is placed correctly. If 
the ligand is docked into the same crystal structure as it is taken from, the process in called re-
docking. To address potential problems, validation by cross-docking or re-docking should 
always be performed, so that necessary adjustments can be made before starting the docking 
job. If having several crystal structures of the protein target, cross-docking is the validation 
method of choice because it is more challenging for the docking program than to just 
reproduce the binding mode of the ligand, and it is more similar to the real docking situation 
(70). 
Protein preparation and grid generation 
Two protein structures were prepared; one with all water molecules deleted and one keeping 
the water molecules located 3Å from hetero-groups (non protein chemical groups, i.e. active 
site iron and substrate/cofactor), in order to see if this made any difference in the docking of 
the cofactor. From the prepared protein structures, two grids were made. We chose a ligand 
diameter midpoint box of x=y=z=22 Å, in order to test and get familiar with the program, 
allowing unusual or asymmetric binding modes using a large grid. All other settings were 
default. 
Ligand preparation 
Metal binding states were added, which generates high pH charges (enabling binding to iron), 
and determine chirality from 3D structure was chosen. All other settings were kept as default. 
When docking rigidly, we do not want the program to generate low energy ligand 
conformations, and this step was omitted in the standard LigPrep procedure. All 
tautomerization and ionization states at pH 5-9 were generated and docked. 
Docking 
BH4, compound IV, L-Tha and L-Nle, were docked using both rigid and flexible docking, and 
in all three modes of precision (HTVS, SP and XP), and the results were compared. They 
were all docked into the grid with no water molecules, and BH4 was also docked flexibly into 
the grid containing some water molecules. Number of poses to keep per ligand was set to 5, 
all other settings were default.  
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To determine how well the ligands docked, we compared the results with reference 
compounds from PDB entries 1j8u (BH4), 4anp (compound IV) (52), 1mmk (Tha) (16) and 
1mmt (Nle) (16), and calculated the root mean square deviation (RMSD), using Discovery 
Studio (71). The references were superimposed onto 1j8u (target protein). 
3.2.4 Docking of the Sigma library 
In addition to neutral pH, we included high pH protonation states for the Sigma ligands, to 
facilitate metal binding. 
Based on the results from the cross-docking, we chose to dock the library in SP-mode. We 
also chose to include water molecules in some of the grids.  
Protein preparation and grid generation 
Five prepared protein structures were generated. Three of them are of the catalytic domain 
and are based on the structure of hPAH in complex with BH4 (1j8u), after removal of the 
cofactor; the first one has all water molecules within 5 Å from hetero-groups included, the 
second one has no water molecules included, and the third one has three water molecules that 
coordinate to iron, included. The two last structures are of the alternative binding sites that 
were detected in LIGSITE (see above); both were generated with no water molecules 
included. All settings were kept default. From these prepared structures, five corresponding 
grids were made (Table 3-2): grid1-1, grid1-2 and grid 1-3 are the grids for the active site. 
Grid2 is the grid for the interface between the dimers, and grid3 is the grid for the interface 
between the monomers.   
Table 3-2: Grids used when docking the Sigma-library.  
Name Description  Water molecules PDB entry 
Grid1-1 Active site All 1j8u 
Grid1-2 Active site None 1j8u 
Grid1-3 Active site Three 1j8u 
Grid2 Interface between dimers None 2pah 
Grid3 Interface between monomers None 1j8u/2pah/1phz 
(hybrid) 
Ligand preparation 
The Sigma-ligands are downloaded as 3D structures, and partial charges were automatically 
assigned when the library was loaded to Glide and converted to the correct format for 
docking.  Further preparation of the ligands was therefore not necessary.   
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Docking 
Docking was performed using flexible docking in SP-mode. Number of poses to keep per 
ligand was set to 1, and the total number of poses was limited to 500. All other settings were 
default.  
Based on their Glide score and structures, 18 compounds were selected to be experimentally 
tested. All 2500 structures were analyzed with Canvas (72-74) using the substructure query-
tool.   
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3.3 Experimental methods 
3.3.1 Thermostability assay 
Differential scanning fluorimetry (DSF) was used to measure the thermal stability of PAH in 
the presence of the hit compounds from the virtual screening. The principle of DSF is to 
measure unfolding of the protein as the temperature is increased. A fluorescent dye (SYPRO 
orange) that interacts with the hydrophobic parts of the protein is added, and fluorescence is 
measured as the protein unfolds upon heating in a PCR machine (75, 76). When the protein 
unfolds, its hydrophobic parts are exposed to the dye, giving a fluorescent signal. The 
fluorescence ranges from 0 to 1, where 1 is the value at which all of the protein is unfolded. 
When the fluorescence is 0.5, 50 % of the protein is unfolded, termed the melting point of the 
protein (Tm). Here, the shift in Tm (ΔTm) when the hit compounds were added to the protein, 
were measured. A positive value indicates that the compound has a stabilizing effect on the 
protein, and a negative value indicates a destabilizing effect. 
The experiment was performed with a 96-well microplate. The enzyme was diluted to 0.05 
mg/mL in FPLC-buffer, and the fluorescent dye, SYPRO orange, was added. The compounds 
were dissolved in 100% DMSO in a concentration of 2 mg/mL, and added to the wells at a 
final concentration of 0.08 mg/mL (2% DMSO). Three controls with 2% DMSO were 
performed.  The plate was heated from 30˚C to 95˚C with a temperature increase of 0.04 ˚C 
per second (4 measurements per degree). The fluorescents signals were detected as the protein 
was unfolded during temperature increase, giving values for Tm and ΔTm.  
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3.3.2 Enzymatic activity assay  
In order to validate if the hit compounds were inhibitors or had a protective effect on PAH 
over time, we assayed their effect on PAH activity. Activity experiments were done using a 
standard PAH activity assay, as described by Knappskog et al (77), but with modifications of 
some of the conditions (Table 3-3 and Table 3-4). The amount of product formed was 
analysed using high performance liquid chromatography (HPLC) equipped with a 
fluorescence detector, after removing the protein by centrifugation. 
Standard PAH activity assay 
The enzyme was diluted to 0.05 mg/mL in FPLC-buffer (20 mM) and BSA (5 mg/mL) and 
kept on ice. BH4 was added to a solution of acidic 2 mM DTT and kept on ice. The activity 
assay was performed at 37 ˚C. 5 µL of the enzyme was added (final concentration 0.005 
mg/mL) to a mixture of 40 mM Hepes-buffer (pH 7), 5 mg/mL catalase and 1 mM 
phenylalanine. The incubation mixture was pre-incubated for 5 minutes. After 4 minutes 10 
µM ferrous ammonium sulphate was added. At 5 minutes the reaction was started by adding 5 
µL of BH4 to a final concentration of 200 µM. The reaction was stopped after 1 minute by 
adding 50 µL stop solution containing 98% ethanol and 2% acidic acid. The reaction mix was 
precipitated at -20 ˚C for at least 30 minutes, and then centrifuged for 10 minutes on 14000 
rmp.  
The amount of product formed was analysed by HPLC. The substrate (L-Phe) and the product 
(L-Tyr) were separated in a column based on their affinity to the stationary phase compared to 
the mobile phase. The stationary phase was a cation exchanger, and the mobile phase was a 
0.1 % acetic acid solution containing 2 % 1-propanol. L-Tyr is more polar than L-Phe because 
of the OH-group that is added during catalysis, and it therefore has a higher affinity to the 
mobile phase and will exit the column first. To determine the amount of produced L-Tyr, a 
fluorescence detector was used, measuring excitation at 274 nm and emission at 304 nm (78). 
The samples were compared to a standard with known concentration, and the specific activity 
was calculated [specific activity PAH = nmolTyr/(mgPAH x min)]. 
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Table 3-3: PAH activity assay. The upper part of the table shows the different components of the assay mixture 
and their concentration. The lower part represents the assay itself, starting at t=0 with the addition of PAH to the 
assay mixture. Pre-incubation time was 5 minutes and reaction time was 1 minute.   
  Original 
concentration 
Volume  
(per sample) 
Assay  
concentration 
Hepes-buffer 250 mM 8. µL 40 mM 
Catalase 10 mg/mL 0.25 µL 0.05 mg/mL 
L-Phe 50 mM 1 µL 1 mM 
H2O  29.75 µL  
MIX 
SUM  39 µL  
t=0 PAH 0.05 mg/mL 5 µL 0.005 mg/mL (0.25 µg) 
t=4 Fe2+ 0.5 mM 1 µL 10 µM 
t=5 BH4 2 mM 5 µL 0.2 mM 
 SUM  50 µL  
t=6 Stop solution  50 µL  
 SUM  100 µL  
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Optimization of activity assay 
The assay was optimized by testing the effects of iron and BSA (bovine serum albumin) on 
the specific activity of PAH, by measuring activity in their presence and absence. The reason 
for testing this was to destabilize the enzyme, but still maintain good activity, which was 
preferable when we later wanted to obtain a destabilization curve for the time dependent 
activity loss of PAH. The purified PAH preparations have amounts of iron varying from 0.45 
to 0.52 iron atoms per subunit PAH (77) (our preparation is assumed to be in the upper 
range), and iron was also being added in the assay to saturate the iron sites and increase the 
activity. BSA is a serum albumine protein that stabilizes the enzyme by acting as a crowding 
agent (for review on molecular crowding and effect on protein stability, see (79)).   
Based on the results, we came up with an assay where additional iron is not added (as in the 
standard protocol for PAH activity), and where BSA is added in the reaction mixture instead 
of being added to the enzyme dilution, as shown in Table 3-4. 
Table 3-4: Optimized PAH activity assay, where iron is removed and BSA added in the mixture. Pre-incubation 
time was 5 minutes and reaction time was 1 minute.   
  Original 
concentration 
Volume 
(per sample) 
Assay 
concentration 
Hepes-buffer 250 mM 8 µL 40 mM 
Catalase 10 mg/mL 0.25 µL 0.05 mg/mL 
L-Phe 50 mM 1 µL 1 mM 
BSA 100 mg/mL 2.5 µL 5 mg/mL 
H2O  28.25 µL  
MIX 
SUM  40 µL  
t=0 PAH 0.05 mg/mL 5 µL 0.005 mg/mL (0.25 µg) 
t=5 BH4/DTT 2 mM 5 µL 0.2 mM 
 SUM  50 µL  
t=6 Stop solution  50 µL  
 SUM  100 µL  
 
Linearity of the specific activity of PAH 
By varying the reaction time from 1 to 10 minutes, we wanted to see for how long the activity 
remained linear (constant specific activity). The measurements have to be performed in the 
linear range of product formation, so that the effects of possible pharmacological chaperones 
are visible.   
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Activity loss as a function of time  
The enzyme was kept on 37 ˚C for 1 to 40 minutes (“pre-pre-incubation time”) before starting 
the assay, in order for us to observe an activity loss over time. 
Testing of the hit compounds  
We tested the effect of individual hit compounds on PAH activity and stability. Compound IV 
was also tested, because we know that it has a stabilizing effect and it is therefore interesting 
to compare with. Two experiments were carried out – the first one with no pre-pre-incubation 
in order to see how the compounds interfere with PAH activity, and the second one with a 
pre-pre-incubation time of 10 minutes to see if any of the compounds can preserve the activity 
and thus stabilize PAH and act as a pharmacological chaperone.  
To make sure that the fluorescent signals detected in HPLC are caused by the produced L-
Tyr, all the compounds were tested to see if they had any natural fluorescence.  
The compounds were dissolved at a concentration of 2 mg/mL in 100% DMSO, and tested at 
a final concentration of 0.04 mg/mL in 2% DMSO, using 96-well micro plates, with one 
control with 2% DMSO on each row. The assays were designed so that each row was assayed 
at the same time using a multi pipette, and the rows were assayed in order from the first one to 
the last one. To get the pre-incubation and reaction time right for each row, the last one was 
done approximately 30 minutes after the first one. The assays were performed at 37 ˚C.  
A varying number of parallels were performed for the controls and for each compound, and 
standard deviation (SD) and standard error (SEM) were calculated, to reflect the variation 
between the parallels (SD) and the precision of the mean value (SEM). A p-value was 
calculated for each compound compared to the control, using the “multiple t-tests”-function in 
Prism (unpaired t-test). This function controls the false discovery rate (FDR) when having 
multiple tests, by performing a Benjamini-Hochberg procedure to determine which p-values 
are small enough to be considered true discoveries (80).  
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Effect on PAH activity 
The mix was added to the wells, and one compound was added to each well. The assay was 
then started.  
Table 3-5: Testing of hit compounds – initial activity assay. The compound was added in the mixture before the 
assay was started at t=0. Pre-incubation time was 5 minutes and reaction time was 1 minute.   
  Original 
concentration 
Volume 
(per sample) 
Assay 
concentration 
Hepes-buffer 250 mM 8 µL 40 mM 
Catalase 10 mg/mL 0.25 µL 0.05 mg/mL 
L-Phe 50 mM 1 µL 1 mM 
BSA 100 mg/mL 2.5 µL 5 mg/mL 
H2O  27.25 µL  
Compound 2 mg/mL  1 µL 0.04 mg/mL 
MIX 
SUM  40 µL  
t =0 PAH  0.05 mg/mL 5 µL 0.005 mg/mL (0.25 µg) 
t =5 BH4/DTT 2 mM 5 µL 0.2 mM 
 SUM  50 µL  
t =6 Stop solution  50 µL  
 SUM  100 µL  
Effect on PAH stability 
The mix was added to the wells. The enzyme (0.05 mg/mL) was pre-pre-incubated with each 
compound (0.4 mg/mL) for 10 minutes at 37 ˚C, before the assay was started by adding 5 µL 
of the enzyme plus compound to the mix.  
Table 3-6: Testing of hit compounds – activity stability assay. The compound was pre-pre-incubated with PAH 
for 10 minutes before the assay was started by adding PAH plus compound to the mix at t=0. Pre-incubation 
time was 5 minutes and reaction time was 1 minute.   
  Original 
concentration 
Volume 
(per sample) 
Assay 
concentration 
Hepes-buffer 250 mM 8 µL 40 mM 
Catalase 10 mg/mL 0.25 µL 0.05 mg/mL 
L-Phe 50 mM 1 µL 1 mM 
BSA 100 mg/mL 2.5 µL 5 mg/mL 
H2O  28.25 µL  
MIX 
SUM  40 µL  
t=0 PAH +  
Compound 
0.05 mg/mL 
0.4 mg/mL  
5 µL 0.005 mg/mL (0.25 µg) 
0.04 mg/mL 
t=5 BH4/DTT 2 mM 5 µL 0.2 mM 
 SUM  50 µL  
t=6 Stop solution  50 µL  
 SUM  100 µL  
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4 RESULTS  
4.1  Target-based virtual screening 
4.1.1 Cross-docking of selected compounds  
The results from the cross-docking are presented in Table 4-1, Table 4-2 and Table 4-3, as 
RMSD values and Glide gscores. The RMSD between the docked ligand and the crystal 
structure (PDB 1j8u) should be as low as possible, indicating that the orientations match. We 
have chosen to define docking of the ligand in the active site with RMSD lower than 2 Å with 
respect to the crystal structure, as successful. 
Table 4-1: Rigid cross-docking of BH4, compound IV, L-Tha and L-Nle to PAH, using HTVS, SP and XP. 
RMSD (compared to PDB 1j8u) and Glide gscore for each compound are displayed. 
Compound  HTVS SP XP 
 RMSD (Å) 
Glide gscore 
(kcal/mol) 
RMSD 
(Å) 
Glide gscore 
(kcal/mol) 
RMSD 
(Å) 
Glide gscore 
(kcal/mol) 
BH4 1.324 -6.435 1.315 -6.504 1.319 -5.640 
Comp.IV 0.8251 -5.659 0.8245 -5.750 0.8451 -3.859 
L-Tha 8.862 -7.887 9.014 -8.047 9.003 -5.737 
L-Nle 8.998 -7.150 9.178 -7.735 9.432 -5.604 
 
Table 4-2: Flexible cross-docking of BH4, compound IV, L-Tha and L-Nle to PAH, using HTVS, SP and XP. 
RMSD (compared to PDB 1j8u) and Glide gscore for each compound are displayed. 
Compound  HTVS SP XP 
 RMSD (Å) 
Glide gscore 
(kcal/mol) 
RMSD 
(Å) 
Glide gscore 
(kcal/mol) 
RMSD 
(Å) 
Glide gscore 
(kcal/mol) 
BH4 1.750 -5.501 1.492 -5.886 1.816 -6.267 
Comp.IV 2.502 -5.148 1.658 -6.562 5.503 -5.405 
L-Tha 8.615 -8.578 8.436 -8.754 8.872 -10.55 
L-Nle 8.889 -7.486 9.095 -7.753 9.957 -10.26 
When comparing rigid and flexible docking, we see that rigid docking gives the best (lowest) 
RMSD values. This is expected, as rigid docking only docks one conformation (the correct 
one), whereas Glide generates ligand conformations internally during the flexible docking 
process, as mentioned earlier. In general, looking at both rigid and flexible docking, we see 
that XP performs poorer that HTVS and SP. According to Schrödinger (personal 
communication with Schrödinger Support), XP seems to be the least accurate when metals are 
involved.   
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Both for BH4 and compound IV, the RMSDs are under 2 Å (1.49 Å and 1.66 Å in SP flexible 
mode). This is particularly good when considering compound IV’s covalent bond to iron 
(metal coordination is a challenge to most docking programs, including Glide). The substrate 
analogues actually got much larger deviations (8.44 Å and 9.10 Å in SP flexible mode).  
The binding modes of the cross-docked compounds are shown in Figure 4-2, and the binding 
mode of BH4 and L-Tha as they appear in their crystal structures are also shown for 
comparison in Figure 4-1. 
 
Figure 4-1: BH4 (blue) in the cofactor binding pocket and Tha (yellow) in the substrate binding pocket (PDB 
1mmk). Iron is shown as a sphere with three coordinating amino acids.  
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Figure 4-2: BH4, compound IV, Nle and Tha (all shown in green) docked to the cofactor binding pocket. 
Reference structures in blue. Iron is shown as a sphere. 
 
We see that the four compounds were all docked into the cofactor binding pocket, including 
the substrate analogues (that we know bind in the substrate binding site, which explains their 
poor RMSD-values).  
BH4 
 
Comp.IV 
 
L-Nle 
 
L-Tha 
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BH4 was successfully re-docked to the cofactor binding site, with an RMSD-value of 1.49 Å 
(SP flexible mode) between the re-docked structure and the crystal structure with all water 
molecules removed. A lower RMSD value was obtained when including water molecules 3 Å 
from BH4 in the grid (0.30 Å), as shown in Table 4-3 and Figure 4-3. 
Table 4-3: SP flexible docking of BH4 using two different grids; one with no waters present and one with water 
molecules within 3 Å from hetero-groups included. 
BH4 grid details RMSD (Å) Glide score (kcal/mol) 
No waters present 1.492 -5.886 
Waters present 0.3028 -11.11 
 
             
Figure 4-3: SP-flexible re-docking of BH4. The re-docked BH4 is shown in green, the original BH4 in blue.   
a) waters excluded from grid b) waters within 3Å from hetero-groups included in grid. Three water molecules 
coordinating to iron are shown in red. 
We see that the re-docked BH4 and BH4 as it appear in the crystal structure, have almost 
identical binding modes when some water molecules are included in the grid, because of  the 
structural water molecules not being replaced by the cofactor upon binding.  
a) b) 
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4.1.2 Docking of the Sigma library 
Table 4-4 shows the selected top hits from the flexible docking of the Sigma library (the 
complete list of all structures is provided upon request). These 18 compounds were bought in 
order to test their binding experimentally. Grid1-1, grid1-2 and grid1-3 are the grids for the 
active site; the first one has all water molecules within 5 Å from hetero-groups included, the 
second one has no water molecules included and the third one has three water molecules 
included. Grid2 is the grid for the interface between the dimers, and grid3 is the grid for the 
interface between the monomers.  
Table 4-4: Selected hits from flexible SP-docking of the Sigma library, with assigned compound numbers, zinc 
ID number, name and 2D structure, Glide gscore and pose number (i.e. ranking). 
Compound 
number 
Zinc ID Structure/name Pose 
number 
Glide 
gscore 
Grid1-1 
 
1 ZINC02540779 
 
5-(3′-hydroxybenzyl)hydantoin 
6 -10.71 
2 ZINC17111121  
N-(4-hydroxy-6-quinazolinyl)acetamide 
25 -9.328 
3 ZINC02038670 
 
4,4′-Diamino[1,1′-biphenyl]-3,3′-diol 
27 -9.313 
4 ZINC26514552 
 
3-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1H-
1,2,4-triazol-5-amine 
28 -9.225 
Grid1-2 
 
5 ZINC05273977  
Tyrosylphenylalanine 
5 -11.491 
6 ZINC06096602  
(2S,3R)-3-Amino-2-hydroxy-4-phenylbutyric 
acid hydrochloride 
8 -11.309 
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7 ZINC03874236 
 
Met-Leu-Phe acetate salt 
14 -11.063 
8 ZINC14632708 
 
(R,S)-4-Fmoc-3-carboxymethyl-piperazin-2-
on 
19 -10.943 
Grid1-3 
 
9 
ZINC01700281 
 
L-Glutamic acid γ-benzyl ester 
2 -10.753 
10 ZINC00153920 
 
7-Hydroxycoumarinyl-4-acetic acid 
5 -10.591 
11 ZINC04284379 
 
2-N-Fmoc-amino-3-(2-N-Boc-amino-
pyrrolidinyl) propionic acid 
19 -10.158 
Grid2 
 
 
12 ZINC27738213 
 
Phe-Arg β-naphthylamide dihydrochloride 
18 -9.475 
13 ZINC05129922 
 
2-Acetyl-1,3-indanedione 
12 -8.377 
14 ZINC03830706 
 
Diminazene aceturate 
16 -8.251 
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15 ZINC04241974 
 
fmoc-D-2-aminomethylphe(boc) 
31 -7.913 
Grid3 
 
16 ZINC00388558 
 
1,3-Diiminoisoindoline 
3 -8.308 
 
17 ZINC15721778  
Nα-Benzoyl-Asn-Gly-Thr amide 
trifluoroacetate salt 
8 -8.092 
18 ZINC26893390 
 
(S)-(-)-2-t-butyl-2-piperazinecarboxamide 
13 -7.7 
Many of the compounds obtained a good score (i.e. large negative Glide gscore number), and 
interact favourably with PAH.  Most of the compounds that docked to the active site appear to 
bind in the cofactor binding pocket and are mainly cofactor- or substrate analogues or small 
peptides. Some of the larger compounds seem to occupy both the cofactor binding site and the 
substrate binding site. See Appendix 1 for binding modes.  
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4.2 Testing virtual hits experimentally 
4.2.1 Effect of the compounds on the thermostability of PAH 
The shift in Tm in the presence of each compound is given in Table 4-5.  
Table 4-5: ΔTm for PAH in the presence of the hit compounds. Tm for the control was 46.7 ± 0.2 ˚C (triplicate). 
Compounds giving a positive shift in Tm is highlighted. 
Compound ΔTm (˚C) Compound ΔTm (˚C) 
1 4.0 10 0 
2 0 11 0 
3 -5.8 12 0 
4 0 13 0 
5 0.6 14 1.1 
6 0 15 -4.1 
7 0.7 16 0 
8 0 17 0 
9 0.6 18 0 
We see that 10 compounds show no effect on thermal stability (ΔTm is zero), 2 compounds 
show a destabilizing effect (negative value of ΔTm), and 6 compounds show a stabilizing 
effect (positive value of ΔTm). The stabilizing effects of compounds 1, 5, 7, 9 and 14 are 
presented in Figure 4-4. 
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Figure 4-4: Fluorescence (given in fluorescence units, FU) plotted against temperature (one measurement per 
compound). The lower panel shows the derivative, for easier visualization of the shifts in Tm. Compound number 
is given in parentheses. The reference is the black line (2% DMSO).  
 
*C04 is just enzyme (without DMSO). This means that DMSO destabilizes with 0.8 ˚C (i.e. not adding DMSO 
increase Tm with 0.8 ˚C). 
 
We see that the lines are shifted to the right of the reference, increasing Tm. The best 
compound (number 1) increases Tm by 4 ˚C.  
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4.2.2  Effect of the compounds on activity of PAH  
Linearity of the specific activity of PAH 
Figure 4-5 shows how much of tyrosine that is produced when the reaction time is varied 
from 1 to 10 minutes (measurements were done at 1, 5 and 10 minutes). The graph shows 
means of three parallels for each time, and the standard error is displayed as error bars (very 
small).  
 
Figure 4-5: The product formation plotted against time (mean of triplicate measurements ± SEM). 
 
We see that the product formation and the time of reaction have an almost linear relationship. 
Being in the linear part of the curve is important (if we continued increasing the reaction time, 
the curve would stop being linear at some point because of increased product concentration in 
the reaction and eventually partial inactivation of PAH), as it allows us to see the effects of 
possible pharmacological chaperones. Also, we see that a reaction time of 1 minute when 
adding 0.25 µg of PAH is sufficient to produce a detectible amount of L-Tyr.  
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Optimization of activity assay 
Figure 4-6 shows how removing BSA and removing iron affect PAH activity. Each column is 
the mean of three parallels, and the standard error is displayed.  
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Figure 4-6: The effect of BSA and iron on PAH activity (mean of triplicate measurements ± SEM) 
 
We see that removing BSA clearly has a large impact on the activity, so we decided to keep it 
in the assay, but instead of having BSA in the enzyme solution, it was added in the assay 
mixture in future experiments. 
In the original assay described by Knappskog et al (77), iron was added the last minute of pre-
incubation. Here, adding iron does not seem to affect the activity, and so we have found that 
when iron is added in the growth medium as described earlier, it is not necessary to add it in 
the assay. This makes it much easier to coordinate the assay times.  
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Activity loss as a function of time  
Figure 4-7 shows the observed activity loss when PAH is kept on 37 ˚C for 1 to 40 minutes 
before the assay is started (“pre-pre-incubation”). Measurements were done at 1, 5, 12, 20, 30 
and 40 minutes, six parallels each time.  
 
Figure 4-7: Relative specific activity plotted against time of pre-pre-incubation (mean of six parallels ± SEM). 
Activity is given as percentages of the activity at 1 minute, which was set to 100 %.   
We measured a reduction of the activity to about 40 % after 12 minutes. This appears to be a 
good starting point for testing how the compounds interfere with PAH activity– if they can 
prevent or reduce the activity loss observed, they can be considered stabilizers for PAH.
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Testing of the hit compounds  
To make sure that the fluorescent signals detected in HPLC were caused by the produced L-
Tyr, all the compounds were tested to see if they had any natural fluorescence. As none of 
them had fluorescence at the same wavelength as L-Tyr, the signals should not be influenced 
by the compounds.  
The results from the testing of the compounds are presented as means of four to eight parallels 
(varying number because of errors in readout of fluorescence, mistakes, or shortage of 
compounds), and given as percentages of the control at 0 min, which was set to 100%. 
Statistical data tables are also presented, including standard deviation (SD), standard error of 
the mean (SEM) and p-values. P-values were calculated using Prism’s “multiple t-tests”-
function. All parallels and statistical data are shown in Appendix 2 and 3. 
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Figure 4-8: The compound’s effect on PAH activity. Initial activity (0 min pre-pre-incubation) is shown next to 
the activity after 10 min pre-pre-incubation. The grids are specified. Compound IV (Comp.IV) is also included. 
The dotted lines represent 100 % activity (control at 0 min) and 63 % activity (control at 10 min). Columns are 
mean of 4-8 parallels ± SEM. 
 
The control has 63% remaining activity after 10 minutes of pre-pre-incubation (with 2% 
DMSO). 10 minutes were chosen as pre-pre-incubation time based on the results from the 
destabilizing curve in figure 4-7. The compounds being able to preserve an activity greater 
than 63% after 10 minutes are considered to be stabilizers.  
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Table 4-6: Statistical data for the initial activity assay (no pre-pre-incubation) showing mean, number of 
parallels, SD, SEM and p-value for each compound. * marks a true discovery, and can be considered a 
significant difference from the control when correcting for multiple testing using FDR. The control was set to 
100 %.  
Compound Mean (%) Number of 
parallels 
SD SEM p-value 
Control 0 min 100.0 20 27.49 6.147  
Comp.IV 122.3 4 28.55 14.28 0.1318 
1 115.1 6 25.34 10.34 0.2296 
2 129.5 6 45.17 18.44 0.0192 
3 34.58 6 8.272 3.377 < 0.0001* 
4 108.5 6 19.80 8.085 0.4986 
5 123.3 6 36.59 14.94 0.0640 
6 125.8 6 40.49 16.53 0.0404 
7 109.0 6 33.26 13.58 0.4737 
8 109,7 7 12.16 4.598 0.4132 
9 90.79 4 18.53 9.264 0.5332 
10 105.9 7 29.1 11.00 0.6186 
11 108.3 6 6.541 2.670 0.5088 
12 89.78 7 16.87 6.376 0.3886 
13 94.84 7 22.94 8.671 0.6632 
14 104.5 6 21.19 8.649 0.7201 
15 93.83 7 16.88 6.378 0.6026 
16 92.05 7 22.75 8.601 0.5024 
17 100.8 7 22.48 8.498 0.9462 
18 93.12 7 12.52 4.732 0.5616 
Looking at the results from the initial assay, we see that very few of the compounds tested 
seem to have a (significant) effect on the initial PAH activity. This is expected, as stabilizing 
effects will not be seen initially, but over time. Compound number 3 appears to be an 
inhibitor. Compound IV, which has previously been shown to be a weak inhibitor (50), does 
not have any significant effect on the initial activity in our experiment (if anything, it 
increases the activity). 
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Table 4-7: Statistical data for the activity stabilization assay (10 min pre-pre-incubation), showing mean, 
number of parallels, SD, SEM and p-value for each compound. The compounds having a higher activity than the 
control (63 %) are highlighted. * marks a true discovery, and can be considered a significant difference from the 
control when correcting for multiple testing using FDR.  
Compound Mean (%) Number of 
parallels 
SD SEM p-value 
Control 0 min 100.0     
Control 10 min 62.76 16 17.7 4.424  
Comp.IV 88.82 4 36.56 18.28 0.0080 
1 25.74 7 11.06 4.181 < 0.0001* 
2 44.63 7 8.965 3.388 0.0227 
3 0 7 0 0 < 0.0001* 
4 50.75 6 14.46 5.902 0.1525 
5 72.62 6 9.587 3.914 0.2399 
6 96.95 6 23.36 9.537 < 0.0001* 
7 78.46 6 9.549 3.899 0.0617 
8 35.11 6 5.567 2.273 0.0011* 
9 46.03 6 12.09 4.934 0.0465 
10 52.25 7 17.15 6.482 0.1858 
11 53.73 7 6.452 2.439 0.2555 
12 32.04 7 8.425 3.184 0.0001* 
13 41.61 7 14.34 5.421 0.0080 
14 60.71 7 15.4 5.82 0.7962 
15 34.01 7 13.6 5.139 0.0003* 
16 42.00 8 16.00 5.658 0.0064 
17 30.42 8 12.39 4.379 < 0.0001* 
18 54.34 8 40.04 14.16 0.2672 
 
Looking at the results from the activity stabilization assay, we see that compound 5, 6 and 7, 
in addition to compound IV, seem to stabilize PAH. Only compound 6 has a statistically 
significant stabilizing effect. The sample with compound 3 apparently has no remaining 
activity after 10 minutes, as expected from the inhibitory effects seen in the initial activity 
assay. 
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5 DISCUSSION 
Although dietary treatment has proven successful to prevent brain damage in PKU patients, 
there is still a great need for treatments that are easier to comply with (1, 35). As PKU is a 
loss-of-function misfolding disease usually caused by mutations in the gene encoding PAH, 
one approach is to attempt to correct the misfolding of the mutant PAH. The potential of 
pharmacological chaperones for this purpose represents a promising approach to treating PKU 
and other misfolding diseases (72). The natural cofactor BH4 has been shown to act as a 
pharmacological chaperone for PAH in high concentrations, but only some patients are 
responsive (36). The pharmacological chaperones compounds III and IV (50), show 
promising effects in cells and normal mice, but the effects are low when tested in mouse 
models of PKU (Aurora Martinez, personal communication). No further development has 
been reported for the compounds discovered by Santos-Sierra et al. (51). Thus, better 
pharmacological chaperones for PAH are necessary.  
In this project, we have screened a virtual library of drug-like compounds by docking them to 
the active site of PAH, and also to alternative binding pockets on the protein surface, with the 
aim of identifying compounds with a pharmacological chaperoning potential for PAH. This 
potential was investigated by evaluating the hit compounds in two in vitro assays, a 
thermostability assay and an activity assay. The use of molecular docking in screening of 
compounds is an established – but also disputed – approach in drug discovery (54-56). This 
thesis contributes to investigate the validity of docking and virtual screening as tools in the 
early phases of drug discovery, particularly in the development of pharmacological 
chaperones.  
The screening identified 18 compounds that underwent thermostability and activity assays. 
One of the compounds has a significant stabilizing effect on PAH activity, and two other 
compounds might also be stabilizers (although not significant). One of the compounds 
inhibits PAH. 
Here follows a discussion of the methods used and the results obtained.   
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5.1 Target-based virtual screening 
There are several docking algorithms and software’s available, with various features and 
different search and scoring functions. A number of papers evaluating the different docking 
performances have been published – however, how to measure docking performance is not 
generally established, and it is therefore difficult to compare these papers. Glide, which is the 
program we have used, is generally appreciated as being one of the most accurate docking 
programs (57, 81).  
An advantage of using virtual screening over traditional approaches in drug discovery, like 
experimental HTS, is the possibility of screening larger databases, containing novel ligands 
that have not yet been synthesized. The ligands can be filtered based on molecular properties, 
which is obviously very useful. Although the screening of large databases is computationally 
demanding, the cost is much lower and the effectiveness much higher, compared to eHTS 
(54-56)).   
A prerequisite for docking is the availability of an x-ray structure of the target protein. 
However, with the sequencing of the human genome and the proteomic research increasing its 
scope, the number of protein targets is also increasing.  
Choice of PDB structures 
There are several crystal structures of PAH available in the Protein Data Bank, and we chose 
PDB 1j8u as target structure for docking to the active site (see Table 3-1). This structure has 
the highest resolution out of the available structures (1.5 Å), and the active site iron is in its 
reduced ferrous state, which is desirable, as this is the catalytically relevant state, as opposed 
to the earlier structures of PAH where the active site iron is in its inactive ferric state. 
Additionally, this structure was solved in complex with the natural cofactor of the enzyme, 
BH4, which has been shown to act as a pharmacological chaperone for PAH (36, 37). There 
are no significant conformational changes observed upon cofactor binding to the catalytic 
domain of PAH (68), and we found the cofactor bound structure to be the most relevant for 
screening compounds towards the active site of PAH. It is important to keep in mind that 
Glide treats the protein receptor as a rigid structure, and the conformational changes that 
occur upon substrate binding, obviously will not happen virtually. We know that Tyr138 
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moves from a position on the outside of the receptor, to a position inside the active site (16) 
when the substrate binds, so it is sensible to use a structure without a bound substrate.  
Docking to binding sites on the protein surface 
Docking to the active site of the target protein is the common procedure. We have also 
docked to two possible binding sites on the protein surface. We believe that investigating 
other sites is important, as there is no good reason to refrain from doing this – interactions 
with residues on the protein surface could stabilize the protein, just as interactions in the 
active site could do so. Ligands that bind in the active site are likely to be inhibitors, and weak 
inhibition seems to be a common feature for pharmacological chaperones (82), but if a ligand 
binds too tightly and exerts considerable inhibition, that would of course not be desirable. It is 
therefore interesting to search for non-inhibitory chaperones that could stabilize the enzyme 
by binding to an alternative binding site. The program used to identify these sites, LIGSITE, 
is shown to have high precision (69), and the sites identified looked sensible when visualizing 
the pockets in Discovery Studio (Figure 3-1). The four active sites in the tetramer were 
correctly identified as binding sites by the program, which is reassuring. There is no crystal 
structure of full-length PAH, and so several structures were combined to make a hybrid 
structure of the tetramer to use as protein target when docking to the surface binding sites 
(Table 3-1). 
5.1.1 Cross-docking of selected compounds  
BH4 and compound IV were both successfully re-docked/cross-docked, whereas the substrate 
analogues seem to dock to the cofactor binding site instead of the substrate binding site 
(Figure 4-2). It could be that the substrate binds to the cofactor binding site in the absence of 
cofactor, which possibly could explain the observed substrate inhibition of PAH at high L-Phe 
concentrations (83). However, this would have to be investigated in more detail to make any 
conclusions. Docking to PAH in complex with its cofactor could have guided the substrate 
analogues into the substrate binding site. However, due to time constraints we could not 
investigate the cross-docking of the substrate analogues any further.  
Metal coordination and water molecules in the active site present a challenge for docking. 
Standard scoring functions are poor at estimating the contribution from possible interactions 
with metals in the receptor. The removal of structural water molecules from the active site 
would allow ligands that are unable to replace these to dock. The inclusion of non-structural 
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water molecules would exclude accessible areas of the active site for ligand to bind. Given 
that BH4 interacts with active site-residues through nearby water molecules, and that 
compound IV coordinates to iron, it is reassuring that both ligands seem to be re-
docked/cross-docked satisfactory (Figure 4-2). Furthermore, we obtained a lower RMSD for 
BH4 when we included water molecules 3 Å from BH4 (0.30 Å) (Figure 4-3), and so deleting 
these seem to have an effect. Based on this we chose to keep water molecules in some of the 
grids when docking the Sigma library. 
Taking a closer look at the results for compound IV, we see that the lowest RMSD-value 
(0.85 Å, SP rigid mode), is accompanied by a less favourable docking score (Table 4-1). This 
suggests that the orientation is correct, but that this orientation is considered unfavourable by 
Glide. The nitrogen atom (N1) of compound IV is non-charged, forming a bond to the iron 
atom, and it seems that Glide would rather prefer a charge on this nitrogen, thus giving the 
non-charged pose a high penalty. This addresses the importance of being aware of the 
limitations of docking when working with structures where metal coordination plays a role – 
if compound IV had been part of a large library that was screened, it would probably not have 
been a hit.  
As both re-docking of BH4 and cross-docking of compound IV produced low RMSD values, 
we concluded that PDB 1j8u was a suitable target protein and that keeping most settings as 
default, as described in section 3.2.3, works satisfactory. Validation of docking to the 
alternative binding sites was not possible to perform, for obvious reasons. 
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5.1.2 Docking of the Sigma-library 
The Sigma-library was chosen because it is easily accessible, and like the other catalogues 
provided by Zinc, it is filtered for drug discovery relevance and considered suitable for 
docking (60, 61). 
The number of hits was limited to 500 compounds per grid. For the three active site-grids, 
many of the compounds are cofactor analogues, phenylalanine analogues or small peptides. 
For grid2 and 3 the compounds are generally larger, and many of them are peptides. In 
general, many of the hit compounds are L-Phe analogues or L-Phe-containing peptides. This 
could be thought to be due to an overrepresentation of this residue in the Sigma-library. A 
substructure search of the Sigma-library identified 1.3% L-Phe-analogues, whereas for our 
hits (all 2500 compounds) the corresponding number was 7.4%. Thus, the original library 
does not have an overrepresentation of L-Phe, suggesting that it provides favourable 
interactions in the binding pockets.  
The 18 hits shown in Table 4-4, were chosen for experimental testing based on their Glide 
score, price and availability, and the fact that we wanted them to represent different types of 
compounds in all grids. Compound 1 is almost identical to one of the pharmacological 
chaperones previously mentioned, identified by Santos-Sierra et al. (51) (they only differ by a 
hydroxyl substituent on the ring for compound 1). 
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5.2 Testing virtual hits experimentally 
By combining DSF with activity experiments, we were able to detect compounds that 
thermally stabilize PAH, and compounds that stabilize by protecting PAH from loosing 
activity.  
5.2.1 Thermostability  
DSF is a quick and easy method for assaying the thermal stability of PAH in the presence of 
the hit compounds. It is time efficient and easy to perform, and it is in fact used as a high 
througput experimental screening of compounds in the lab (75, 76). Here, it is used to 
complement the activity data.  
Six compounds increase the melting point of PAH (Figure 4-4), compound number 1 giving 
the largest increase (4˚C), suggesting that it has a stabilizing effect on the PAH structure. This 
compound (hydroxybenzylhydantoin) is a cofactor analogue (see structure in Table 4-4) that, as 
previously mentioned, is very similar to benzylhydantoin, which is the pharmacological 
chaperone identified by Santos-Sierra et al. (51). They used ligand-based virtual screening in 
the search for compounds with similar properties as BH4. Compound 1 docked to one of the 
water molecule-containing grids (grid1-1), that were generated based on the observation that 
this grid was optimal for re-docking of the cofactor (Table 4-3). A closer investigation of the 
compounds giving high docking score with grid1-1 reveals that they have similar interactions 
with PAH as the cofactor (Appendix 1). This suggests that inclusion of water molecules when 
preparing the grid for docking is the optimal approach to identify compounds that have the 
same binding properties as the cofactor. In general, this target-based approach of course 
requires that the compound for which analogues are being pursued, is available in complex 
with its receptor, with water molecules included.  
Two compounds decrease the melting point (compound 3 with -5.8 ˚C and compound 15 with 
-4.1 ˚C). These two compounds presumably destabilize the folded state, which is not a 
desirable feature of a pharmacological chaperone. We chose to keep also these compounds for 
further validation by activity measurements.  
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5.2.2 Enzymatic activity 
Several activity assays were performed, as described in section 3.3.2. The standardized PAH 
activity assay has a pre-incubation with L-Phe for five minutes, where iron is present the last 
minute of pre-incubation, before the reaction is started. This procedure ensures that PAH is 
fully activated by the time the reaction starts (77).  
Optimization of the activity assay 
We found that adding iron to the reaction mixture did not increase the activity of the enzyme 
(Figure 4-6). This is contrary to what was found in the original paper where the procedure for 
activity measurements is presented (77). However, we added iron to the media when PAH 
was expressed by the bacteria, which presumably have saturated the purified enzyme with 
iron. BSA is traditionally used as a crowding agent to stabilize the enzyme in diluted 
solutions. When removing BSA from the pre-pre-incubation, we can observe a reduction in 
activity over a relatively short time frame (60 % reduction in 12 minutes of pre-pre-
incubation) (Figure 4-7), which is reasonable for testing the effect of our potential 
pharmacological chaperones. Additionally, the presence of BSA during pre-pre-incubation 
with hit compounds could potentially diminish the effect of our compounds.  
Testing of the compounds 
As the assays were done manually with pipettes, some differences between and within rows 
on the plate are unavoidable. There could also be time dependent differences within one plate, 
as the last row was done about 30 minutes after the first one. We do have controls on each 
row, and so we could have presented activities as percentages of the control on the same row 
to account for this. However, the variance between controls seems to be random. By 
presenting activities as percentages of the activity of the mean of the controls at 0 min, we are 
able to plot the results from the initial assay and the pre-pre-incubation assay together, 
providing more satisfactory comparisons.  
Looking at Figure 4-8, we see that out of the compounds tested, compound 3 had a significant 
inhibitory effect on PAH activity, and compound 6 showed a significant protective effect on 
PAH activity. Also compounds 5 and 7 seem to be stabilizers, but these effects were not 
statistically significant. There is a large standard deviation for some of the compounds, 
reflecting high variability between the parallels. This could be due to different conditions 
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(concentration of enzyme, concentration of BH4, concentrations of components in the mix 
solution etc.), inaccurate timing of addition of enzyme, BH4 and stop solution, aggregation, 
poor mixing, and errors concerning the separation on the HPLC column and readout of 
fluorescence.  
Compound IV has been shown to inhibit PAH to some extent (50). Our results suggest the 
opposite. This could be due to a stabilizing effect already seen in the initial activity assay – 
even though there is no pre-pre-incubation, the compounds are present together with PAH in 
the 5 minute pre-incubation with L-Phe. This applies to all of the compounds, and we can not 
rule out an initial stabilizing effect.  
The controls lost on average 40 % of their activity during 10 minutes of pre-pre-incubation 
with DMSO, compared to 60 % activity loss during 12 minutes of pre-pre-incubation without 
DMSO (as seen in the destabilization curve in Figure 4-7). The differences observed are 
likely due to effects of adding DMSO and the 2 minutes that differ in the pre-pre-incubation 
times.  
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5.3  Novel compounds with an effect on PAH 
Looking at the results all together, the screening did identify several compounds that affect 
PAH. There is little consistency between the results from DSF and the activity experiments.  
The process of measuring protein stability is not straight forward, and we can not know the 
exact mechanisms of stabilization. Enzymatic activity is crucial for the protein function, and 
based on this we have considered it to be the most reliable measure to monitor protein 
stabilization in this project. Thus, compound 6 in particular, but also 5 and 7, appear to 
stabilize PAH. Compound 6 showed no effect on the melting point of the protein, and 
compounds 5 and 7 increased Tm with 0.6 and 0.7 ˚C, respectively, but as these values are 
very small and based on single measurements, they cannot be considered significant. 
Compound 3 stands out as a definite inhibitor, and it is conflicting that it appears to 
destabilize the protein structure (decrease Tm).  
PAH stabilizers 
 
 
Figure 5-1: Ligand interaction diagram for compound 6 ((2S, 3R)-3-amino-2-hydroxy-4-phenylbutyric acid). 
Amino acids are coloured by residue type (red: acidic, green: hydrophobic, blue: polar/metal, grey: other).  
Compound 6 ((2S, 3R)-3-amino-2-hydroxy-4-phenylbutyric acid (AHPA)) is a substrate 
analogue that binds in the cofactor binding site (Appendix 1). It showed a significant 
stabilizing effect on PAH (97% remaining activity after 10 minutes compared to 63% for the 
control). It also appear to be a better stabilizer than compound IV (89% remaining activity) in 
our experiment, and it therefore has a great potential as a pharmacological chaperone for 
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PAH, and a possible future drug candidate for PKU. The AHPAs are shown to be 
enkephalinase inhibitors that potentiate the analgesic effect of morphine (84, 85). This 
implicates that compound 6 is not specific for PAH, and because it apparently penetrates the 
blood-brain-barrier (BBB), it is likely to affect the other AAAHs as well. However, the fact 
that this compound already has been studied makes it easier to access information about its 
properties and uses, and the structure could be further modified to be more specific to PAH. It 
meets the criteria of Lipinski’ rule of five, which is a way of evaluating the “druglikeness” of 
a compound, i.e. whether a compound is likely to be successfully orally administrated in 
humans (86).  
 
Figure 5-2: Ligand interaction diagram for compound 5 (tyrosylphenylalanine). Amino acids are coloured by 
residue type (red: acidic, green: hydrophobic, blue: polar/metal, grey: other  
 Compound 5 (tyrosylphenylalanine) is a dipeptide that binds in the cofactor binding site. The 
presence of this compound resulted in a remaining PAH activity of 73% after 10 minutes pre-
pre-incubation (compared to 63% for the control). This effect is not statistically significant, 
and more testing would be necessary to draw any conclusions. Peptides are generally difficult 
drug candidates, because of their susceptibility to degradation. However, modification of  
peptide structures into synthetic, more stable compounds that mimic the natural peptides (i.e. 
peptidomimetics) represents a promising field in drug design (see review (87)).  
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Figure 5-3: Ligand interaction diagram for compound 7 (methionyl-leucylphenylalanine). Amino acids are 
coloured by residue type (red: acidic, green: hydrophobic, blue: polar/metal, grey: other) 
Compound 7 (metionyl-leucylphenylalanine acetate) is a tripeptide that binds in the active site 
pocket (extends through the cofactor binding site and the substrate binding site, see Appendix 
1). The presence of this compound resulted in a remaining PAH activity of 78% after 10 
minutes pre-pre-incubation (compared to 63% for the control). This effect is not statistically 
significant, and more testing would be necessary to draw any conclusions. Compound 7 has 
weak chemotactic properties, which has been utilized to design a peptide-grafted liposomal 
delivery system targeted to macrophages (88), and Primoquine (antiprotozoal drug) can be 
delivered this way. The same peptide issues concerning drug potential apply to compound 7. 
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Figure 5-4: Binding modes of compound 6 (green), compound 5 (yellow) and compound 7 (purple) in the active 
site. Iron is also shown as a sphere. Oxygen atom near iron is coloured red, and represents a possibility of 
coordination to iron. Phenylalanine rings, or phenylalanine-like rings in the case of compound 6, are coloured 
grey for comparison of their positions.  
All three stabilizers have in common that they are either L-Phe analogues or peptides 
containing L-Phe. The phenylalanine-like ring are located in different positions, as illustrated 
in figure 5-4: for compound 5 the ring is located in the opposite end of the cofactor binding 
site compared to compound 6, and for compound 7 it is located in the substrate binding site. 
All compounds show a possible coordination to iron through the oxygen atom.   
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PAH inhibitor 
 
 
Figure 5-5: Ligand interaction diagram for compound 3 (4,4′-Diamino[1,1′-biphenyl]-3,3′-diol). Amino acids 
are coloured by residue type (red: acidic, green: hydrophobic, blue: polar/metal, grey: other  
  
 
Because of the strong inhibitory effects seen with compound 3 (4,4′-Diamino[1,1′-biphenyl]-
3,3′-diol), it is worth mentioning, even though inhibition of PAH is not desirable. However, it 
could be of interest in in vitro assays where inducing PKU would be relevant. PAH activity 
goes from 34% initially in the presence of compound 3, to no activity after 10 minutes. 
Several of the compounds show inhibitory effects, but none as pronounced as compound 3.  
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6 FUTURE PERSPECTIVES 
Out of the stabilizers, two of the compounds do not show a strictly significant stabilizing 
effect, probably because of variations between parallels. For these, the experiments should be 
repeated in order to validate our findings. Further optimization of affinity of the compounds 
towards PAH and screening for compound analogues could lead to increased stabilizing 
effects. Insight in all thermodynamic binding properties could for example be obtained by 
using isothermal titration calorimetry (ITC). 
As selectivity for PAH is desirable, the compounds need to be tested on TH and TPH. 
Implications of stabilizing or inhibitory effects on the other AAAHs should be considered 
carefully, as well as the possibility of modifying the compounds to be more selective to PAH, 
if selectivity is an issue. 
We have only tested the compounds on wt-PAH, and testing on specific mutants would be 
relevant and could open up to individualized treatment of different PKU genotypes.  
For the compounds to be applicable as drug candidates for treating PKU, they would have to 
be tested in cells and further in animal models, to explore activity and toxicity, and eventually 
pharmacokinetic properties. 
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7 CONCLUDING REMARKS 
By combining virtual and experimental methods, we have identified a potential 
pharmacological chaperone that is able to protect PAH from loosing activity, and therefore 
could be considered a possible candidate to treat PKU. We have also identified two peptides 
that show non-significant stabilizing effects and require further testing for them to be 
considered as potential pharmacological chaperones for PAH. A PAH inhibitor which might 
show interesting biotechnological approaches was also discovered.  
The approach taken here, with target-based virtual screening and experimental validation of 
hits could be applied to other targets to find possible stabilizers or inhibitors.  
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9 APPENDIX 
 
Appendix 1 
Docking of compounds 1-18. Iron is shown as an orange sphere, and the compounds are 
coloured by element.  
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Appendix 2 
 
All parallells (designated P) and statistical calculations for the initial activity assay, printed 
from GraphPad Prism. Activity is given in percentage of the mean of the controls. 
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Appendix 3 
 
All parallells (designated P) and statistical calculations for the stability activity assay, printed 
from GraphPad Prism. Activity is given in percentage of the mean of the controls in the initial 
assay. 
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